EAM
MYGN icon

EverPoint Asset Management’s Myriad Genetics MYGN Stock Holding History

EverPoint Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-480,000
Closed -$17M – 545
2015
Q1 		$17M Buy
480,000
+5,000
+1% +$179K 0.32% 87
2014
Q4 		$16.2M Buy
+475,000
New +$16.9M 0.36% 92

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EverPoint Asset Management's MYGN Position: Q2 2015 in Review

EverPoint Asset Management sold out of Myriad Genetics (MYGN) in Q2 2015, closing a stake of 480,000 shares — an estimated $17M sold.

EverPoint Asset Management first reported a position in MYGN in Q4 2014 and held it in 2 quarters. The position peaked at $17M in Q1 2015. 234 funds tracked by Wall St. Rank hold MYGN as of Q2 2015.

  • EverPoint Asset Management reported no remaining Myriad Genetics position as of Q2 2015 after selling out during the quarter.
  • EverPoint Asset Management sold 480,000 Myriad Genetics shares in Q2 2015, an estimated $17M.
  • EverPoint Asset Management first reported a position in Myriad Genetics in Q4 2014 and held it in 2 quarters.
  • EverPoint Asset Management's Myriad Genetics position peaked at $17M in Q1 2015.
  • 234 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2015.

Based on EverPoint Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.